首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   7篇
  免费   0篇
水产渔业   1篇
畜牧兽医   6篇
  2011年   1篇
  2010年   1篇
  2005年   2篇
  1993年   1篇
  1990年   1篇
  1976年   1篇
排序方式: 共有7条查询结果,搜索用时 15 毫秒
1
1.
2.
3.
Arterioportal fistulae are rare congenital anomalies of the hepatic vasculature. Diagnosis is conventionally made by selective angiography or ultrasonography. This report describes use of a dual-phase computed tomographic (CT) angiographic technique to diagnose arterioportal fistulae in four dogs. Advantages of this method include a noninvasive peripheral injection of contrast medium, ability to diagnose multiple acquired extrahepatic shunts, and observation of hemodynamic changes such as hepatofugal blood flow and reduced circulation to the caudal abdomen. The hepatic vasculature including arteries, veins, and portal veins can be completely evaluated. Dual-phase CT angiography is a safe and minimally invasive method of diagnosing arterioportal fistulae in dogs.  相似文献   
4.
5.
We describe the technique for in vivo cardiac‐gated magnetic resonance imaging (MRI) in normal dogs and its application in two dogs with a large right atrial tumor. The dogs with a cardiac tumor were also imaged using contrast‐enhanced magnetic resonance angiography (CE‐MRA). Cardiac‐gated MRI and CE‐MRA are both feasible in animals with short acquisition times compatible with breath‐hold imaging under anesthesia, and provide detailed two‐ and three‐dimensional (3D) depiction of the cardiac anatomy and great vessels with or without contrast medium. Although cardiac MRI will not replace echocardiography, it is a powerful alternative technique to use when knowledge of the 3D anatomy of the vasculature is required, when precise volume measurements are needed or when myocardial characterization is indicated. As opposed to contrast‐enhanced computed tomography angiography, cardiac MRI does not use ionizing radiation or iodinated contrast medium.  相似文献   
6.
SUMMARY The efficacy of one administration of moxidectin against natural infestations of the 3 common species of cattle lice in Australia: Linognathus vitull, Damallnla bovls and Haematoplnus eurysternus, was determined. A high degree of control of L vituli (too long-nosed sucking louse) was achieved with both the cattle Injection (96.7% and 100%) at 0.2 mg/kg and the cattle pour-on formulation (94.6% and 100%) at 0.5 mg/kg on the 2 farms where this louse occurred. An Injection of moxidectin at 0.2 mg/kg did not eliminate D bovis. In these trials efficacy ranged from nll to 85.2%. In contrast the pour-on formulation at 0.5 mg/kg provided consistently high efficacy (83.6 to 100%) against D bovis on 3 farms. Infestations of H eurysternus (the short-nosed sucking louse) were low and no significant difference was recorded between treatment groups In a single trial, however, lice persisted on 3 to 7 cattle In the untreated group at each Inspection, whereas none were found on any animals in the 2 groups treated with moxidectin on Inspection after treatment.  相似文献   
7.
Contrast‐enhanced multiphase magnetic resonance angiography (CE‐MRA) was used in 17 dogs with a suspected congenital portal vascular anomaly. Portal vascular anomalies were identified in 16 of the 17 dogs. Eleven had a single intrahepatic portocaval shunt (two central divisional, three right divisional, and six left divisional), one dog had a double intrahepatic portocaval shunt, one dog had a hepatic arteriovenous malformation, one dog had a complex intrahepatic porto‐caval shunt. Two dogs had an extrahepatic portosystemic shunt and no shunt was identified in one dog. Total imaging time was <10 min and image quality was good to excellent in all dogs. Portal CE‐MRA is a feasible, fast and non invasive technique to diagnose portal vascular anomalies in dogs, with a large field‐of‐view and good anatomic depiction of the abnormal vessels. Based on these results, CE‐MRA is an efficient imaging technique for the diagnosis of portal vascular anomalies in dogs.  相似文献   
1
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号